UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in its Charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including
area code: (
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name
of each exchange on which registered | ||
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. | Other Events. |
The Adjourned Cellectar Annual Meeting of Stockholders Reconvenes Friday, June 23, 2023
On June 14, 2023, Cellectar Biosciences, Inc., (the “Company”) convened and then determined to adjourn its 2023 Annual General Meeting of Stockholders (the “Annual Meeting”), because the Company did not have a sufficient number of shares of the Company’s common stock present in person or represented by proxy at the Annual Meeting to have constituted a quorum. The adjourned meeting will reconvene on Friday, June 23, 2023 at 10:00 A.M., local time, at the Company’s headquarters at 100 Campus Drive, Florham Park, New Jersey 07932.
The close of business on April 25, 2023 will continue to be the record
date for the determination of stockholders of the Company entitled to vote at the Annual Meeting. Stockholders of the Company who have
previously submitted their proxy or otherwise voted and who do not want to change their vote do not need to take any action.
No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Company encourages all of its stockholders to read the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2023 (the “Proxy Statement”), which is available on the SEC’s website at www.sec.gov, on the Company’s website at https://investor.cellectar.com/sec-filings and on the voting platform at www.proxyvote.com.
The Company will continue to solicit votes from its stockholders with respect to the proposals set forth in the Proxy Statement. The Company encourages all stockholders who have not yet voted to do so before Thursday, June 22, 2023 at 11:59 p.m., Eastern Time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CELLECTAR BIOSCIENCES, INC. | ||
Date: June 14, 2023 | By: | /s/ Chad J. Kolean |
Name: | Chad J. Kolean | |
Title: | Chief Financial Officer |
Cover |
Jun. 14, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jun. 14, 2023 |
Entity File Number | 1-36598 |
Entity Registrant Name | Cellectar Biosciences, Inc |
Entity Central Index Key | 0001279704 |
Entity Tax Identification Number | 04-3321804 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 100 Campus Drive |
Entity Address, City or Town | Florham Park |
Entity Address, State or Province | NJ |
Entity Address, Postal Zip Code | 07932 |
City Area Code | 608 |
Local Phone Number | 441-8120 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.00001 per share |
Trading Symbol | CLRB |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end
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